menu
    • menu
    [{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Palbociclib","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"ZN-c5","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ZN-d5","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Zentalis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Tybourne Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"ZN-c5","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Tybourne Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Tybourne Capital Management"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ZN-c5","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Abemaciclib","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Zentalis Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Zentalis Pharmaceuticals"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ZN-c3","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zentalis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Niraparib tosylate","moa":"WEE1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Zentalis Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Zentalis Pharmaceuticals \/ Zentalis Pharmaceuticals"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"ZN-c3","moa":"WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ OrbiMed","highestDevelopmentStatusID":"8","companyTruncated":"Zentalis Pharmaceuticals \/ OrbiMed"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ZN-d5","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zentalis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ZN-c3","moa":"WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zentalis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"SU2C Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"ZN-c3","moa":"WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ SU2C Catalyst","highestDevelopmentStatusID":"8","companyTruncated":"Zentalis Pharmaceuticals \/ SU2C Catalyst"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ZN-D5","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"ZN-c3","moa":"WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Caris Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Zentalis Pharmaceuticals \/ Caris Life Sciences"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Azenosertib","moa":"WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Azenosertib","moa":"WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Azenosertib","moa":"WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Zentalis Pharmaceuticals \/ Pfizer"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"WEE1","graph1":"Oncology","graph2":"Preclinical","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"4","companyTruncated":"Zentalis Pharmaceuticals \/ Pfizer"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Azenosertib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Immunome","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ZPC-21","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Zentalis Pharmaceuticals","amount2":0.31,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.31,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Immunome","highestDevelopmentStatusID":"4","companyTruncated":"Zentalis Pharmaceuticals \/ Immunome"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Azenosertib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Azenosertib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zentalis Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Zentalis Pharmaceuticals

    Menu

    Zentalis Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azenosertib,Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zentalis Pharmaceuticals Reports FDA Lifts Partial Clinical Hold on Azenosertib Studies

                            Details : ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.

                            Brand Name : ZN-c3

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 16, 2024

                            Lead Product(s) : Azenosertib,Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azenosertib,Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

                            Details : ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.

                            Brand Name : ZN-c3

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 18, 2024

                            Lead Product(s) : Azenosertib,Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZPC-21

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Immunome

                            Deal Size : $310.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Immunome Licenses Zentalis ROR1 Antibody-Drug Conjugate and Technology Platform

                            Details : Immunome licenses Zentalis’ ZPC-21, a preclinical ROR1 ADC with IND submission planned for Q1 2025, utilizing Zentalis’ ADC platform technology.

                            Brand Name : ZPC-21

                            Molecule Type : Large molecule

                            Upfront Cash : $35.0 million

                            January 08, 2024

                            Lead Product(s) : ZPC-21

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Immunome

                            Deal Size : $310.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azenosertib,Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing

                            Details : ZN-c3 (azenosertib) is a potentially first-in-class and best-in-class small molecule WEE1 inhibitor in development for the treatment of ovarian cancer and uterine serous carcinoma.

                            Brand Name : ZN-c3

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 06, 2023

                            Lead Product(s) : Azenosertib,Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azenosertib,Encorafenib,Cetuximab

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer

                            Details : Zentalis and Pfizer will initiate a Phase 1/2 dose escalation study of ZN-c3 in combination with encorafenib and cetuximab—an FDA-approved standard of care known as the BEACON regimen—in patients with BRAF V600E-mutated metastatic colorectal cancer (...

                            Brand Name : ZN-c3

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 24, 2022

                            Lead Product(s) : Azenosertib,Encorafenib,Cetuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azenosertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $25.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer

                            Details : Zentalis intends to use the net proceeds of the offering to help fund ongoing and planned clinical trials, including studies of ZN-c3, its Wee1 inhibitor, and ZN-d5, its BCL-2 inhibitor, and for working capital and general corporate purposes.

                            Brand Name : ZN-c3

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 27, 2022

                            Lead Product(s) : Azenosertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $25.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azenosertib,Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR

                            Details : ZN-c3 showed robust clinical activity in an advanced, sicker patient population (57% had prior pembrolizumab/lenvatinib use), specifically demonstrating a deepening of tumor response, which included one patient who achieved an unconfirmed complete respon...

                            Brand Name : ZN-c3

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 11, 2022

                            Lead Product(s) : Azenosertib,Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azenosertib,Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients wi...

                            Details : ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all chemotherapy cohorts, also exhibit a better hematologic and gastrointestinal tolerability profile within We...

                            Brand Name : ZN-c3

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 08, 2022

                            Lead Product(s) : Azenosertib,Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azenosertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Caris Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies,...

                            Details : Through this partnership, Caris will sequence individuals’ complete exome and transcriptome, leverage real-world data to help inform clinical development and help identify eligible patients for Zentalis’ clinical trials.

                            Brand Name : ZN-c3

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 29, 2022

                            Lead Product(s) : Azenosertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Caris Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Zentalis Pharmaceuticals

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZN-D5

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1/2 Study of BC...

                            Details : First patient is dosed for ZN-d5, oral selective BCL-2 inhibitor candidate for hematologic malignances and related disorders, in patients with AL amyloidosis, based on ZN-d5’s optimized, selective design.

                            Brand Name : ZN-D5

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 22, 2022

                            Lead Product(s) : ZN-D5

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth